Fewer than one in 10 people eligible to benefit from obesity jabs like Wegovy can access them, states the World Health Organization as it releases its first advice on the therapies.
Given in excess of 1,000,000,000 individuals worldwide now obese, it is urging more widespread and fairer availability to these injectable treatments.
Based on estimates, over two billion are projected to be obese by 2030 if no action is taken.
"Our new guidelines recognises that obesity is a chronic disease that can be managed with thorough and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are major obstacles to widespread access to the treatments that can assist patients in reducing significant weight, notes the body.
Skinny Jab Supply Crisis
Even in the current best projected outlook, the production of such drugs might only reach approximately 100 million people – under 10% of those who need them, as stated by the WHO.
The guideline encourages countries and companies to expand availability, through approaches including licensing agreements.
Exclusive production rights on semaglutide – the main ingredient of Novo Nordisk's Wegovy – is due to expire in a number of nations in 2026.
The Way Weight-Loss Jabs Operate
These medications mimick a body's own hormone to slow digestion, reduce hunger and boost feelings of fullness so people reduce food intake.
Individuals usually see weight reduction after several weeks of starting on the weekly injections.
Studies indicates people may put most of the weight back on within a year of halting the medication, because their typical food cravings return.
To be above a healthy weight elevates your likelihood for experiencing medical conditions, like type 2 diabetes, heart disease, stroke, and specific malignancies.
Excess weight affects individuals in all nations and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.
